Menu
US
Shop
Request a Quote
Contact Us
US
img-dual-car-t-cells1920x640
Whitepaper

Transforming cell therapies with dual CAR strategies

CAR T-cell therapy has shown some remarkable success including several market approvals. However, challenges remain such as antigen escape, tumor heterogeneity, and solid tumors.

Dual CAR T-cell therapy has emerged as an innovative strategy that has the potential to overcome these limitations.

In this white paper, you will learn about:

  • The evolution of CAR design
  • The potential advantages of dual CAR constructs
  • Manufacturing challenges associated with their clinical translation
  • How Revvity’s LentiBOOST™ transduction enhancer and BioLegend’s Cell-Vive™ reagents can help to optimize manufacturing processes

LentiBOOST Pharma-Grade: For research use only. Not for use in diagnostic procedures.
LentiBOOST GMP Grade: Not for diagnostic use. Other applications must be authorized by a license from Revvity.
Cell-Vive™ GMP: For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Download Resource

Transforming cell therapies with dual CAR strategies

Download Whitepaper